Brown Brothers Harriman & Co. Makes New $45,000 Investment in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Brown Brothers Harriman & Co. acquired a new position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $45,000.

Several other large investors have also recently added to or reduced their stakes in GLSI. JPMorgan Chase & Co. lifted its holdings in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock worth $79,000 after buying an additional 4,465 shares in the last quarter. Barclays PLC lifted its holdings in shares of Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Garden State Investment Advisory Services LLC acquired a new position in shares of Greenwich LifeSciences in the 3rd quarter valued at approximately $253,000. State Street Corp increased its stake in Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock worth $1,919,000 after acquiring an additional 5,861 shares during the period. 4.16% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Snehal Patel bought 2,500 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was bought at an average price of $12.51 per share, with a total value of $31,275.00. Following the completion of the acquisition, the chief executive officer now owns 5,552,502 shares of the company’s stock, valued at $69,461,800.02. This represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 51.67% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Greenwich LifeSciences Stock Up 1.0 %

NASDAQ:GLSI opened at $9.35 on Thursday. Greenwich LifeSciences, Inc. has a 12-month low of $9.06 and a 12-month high of $18.75. The stock’s 50 day moving average price is $11.88 and its two-hundred day moving average price is $12.87. The firm has a market capitalization of $122.91 million, a price-to-earnings ratio of -11.69 and a beta of 1.69.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.